Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1

Patrick J. Hensley; Roland Seiler; Harry Herr; Kent W. Mouw; Gopa Iyer; Lars Dyrskjøt; Roman Nawroth; Peter Goebell; Bernd Schmitz-Drager; Tilman Todenhofer; Peter C. Black; Ashish M. Kamat; Stephen B. Williams

doi:10.1016/j.urolonc.2023.01.001

Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1

Patrick J. Hensley, Roland Seiler, Harry Herr, Kent W. Mouw, Gopa Iyer, Lars Dyrskjøt, Roman Nawroth, Peter Goebell, Bernd Schmitz-Drager, Tilman Todenhofer, Peter C. Black, Ashish M. Kamat, Stephen B. Williams

Urology

Research output: Contribution to journal › Review article › peer-review

Abstract

The morbidity associated with radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) has fueled investigations into the feasibility of bladder preservation strategies after a favorable clinical response to neoadjuvant therapy (NAT). Identifying optimal candidates for bladder preservation is predicated on our ability to identify tumors with inherent cisplatin sensitivity and accurately stage patients before and after NAT. In the present review, we evaluate the accuracy and limitations of contemporary staging modalities and investigate clinical outcomes in patients with MIBC who were managed with bladder preservation after NAT. Lastly, we discuss the predictive role of cisplatin-sensitizing DNA damage response (DDR) gene alterations as a foundational component to current prospective clinical trials evaluating bladder preservation in the setting of MIBC.

Original language	English (US)
Pages (from-to)	307-312
Number of pages	6
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	41
Issue number	7
DOIs	https://doi.org/10.1016/j.urolonc.2023.01.001
State	Published - Jul 2023

Keywords

Bladder cancer
DNA damage response
Genetic alteration
Neoadjuvant therapy
Predictors

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/j.urolonc.2023.01.001

Cite this

Hensley, P. J., Seiler, R., Herr, H., Mouw, K. W., Iyer, G., Dyrskjøt, L., Nawroth, R., Goebell, P., Schmitz-Drager, B., Todenhofer, T., Black, P. C., Kamat, A. M., & Williams, S. B. (2023). Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1. Urologic Oncology: Seminars and Original Investigations, 41(7), 307-312. https://doi.org/10.1016/j.urolonc.2023.01.001

Hensley, PJ, Seiler, R, Herr, H, Mouw, KW, Iyer, G, Dyrskjøt, L, Nawroth, R, Goebell, P, Schmitz-Drager, B, Todenhofer, T, Black, PC, Kamat, AM & Williams, SB 2023, 'Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1', Urologic Oncology: Seminars and Original Investigations, vol. 41, no. 7, pp. 307-312. https://doi.org/10.1016/j.urolonc.2023.01.001

@article{f14af72337f142bfaf8c99b161239fdb,

title = "Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1",

abstract = "The morbidity associated with radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) has fueled investigations into the feasibility of bladder preservation strategies after a favorable clinical response to neoadjuvant therapy (NAT). Identifying optimal candidates for bladder preservation is predicated on our ability to identify tumors with inherent cisplatin sensitivity and accurately stage patients before and after NAT. In the present review, we evaluate the accuracy and limitations of contemporary staging modalities and investigate clinical outcomes in patients with MIBC who were managed with bladder preservation after NAT. Lastly, we discuss the predictive role of cisplatin-sensitizing DNA damage response (DDR) gene alterations as a foundational component to current prospective clinical trials evaluating bladder preservation in the setting of MIBC.",

keywords = "Bladder cancer, DNA damage response, Genetic alteration, Neoadjuvant therapy, Predictors",

author = "Hensley, {Patrick J.} and Roland Seiler and Harry Herr and Mouw, {Kent W.} and Gopa Iyer and Lars Dyrskj{\o}t and Roman Nawroth and Peter Goebell and Bernd Schmitz-Drager and Tilman Todenhofer and Black, {Peter C.} and Kamat, {Ashish M.} and Williams, {Stephen B.}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = jul,

doi = "10.1016/j.urolonc.2023.01.001",

language = "English (US)",

volume = "41",

pages = "307--312",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1

AU - Hensley, Patrick J.

AU - Seiler, Roland

AU - Herr, Harry

AU - Mouw, Kent W.

AU - Iyer, Gopa

AU - Dyrskjøt, Lars

AU - Nawroth, Roman

AU - Goebell, Peter

AU - Schmitz-Drager, Bernd

AU - Todenhofer, Tilman

AU - Black, Peter C.

AU - Kamat, Ashish M.

AU - Williams, Stephen B.

PY - 2023/7

Y1 - 2023/7

N2 - The morbidity associated with radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) has fueled investigations into the feasibility of bladder preservation strategies after a favorable clinical response to neoadjuvant therapy (NAT). Identifying optimal candidates for bladder preservation is predicated on our ability to identify tumors with inherent cisplatin sensitivity and accurately stage patients before and after NAT. In the present review, we evaluate the accuracy and limitations of contemporary staging modalities and investigate clinical outcomes in patients with MIBC who were managed with bladder preservation after NAT. Lastly, we discuss the predictive role of cisplatin-sensitizing DNA damage response (DDR) gene alterations as a foundational component to current prospective clinical trials evaluating bladder preservation in the setting of MIBC.

AB - The morbidity associated with radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) has fueled investigations into the feasibility of bladder preservation strategies after a favorable clinical response to neoadjuvant therapy (NAT). Identifying optimal candidates for bladder preservation is predicated on our ability to identify tumors with inherent cisplatin sensitivity and accurately stage patients before and after NAT. In the present review, we evaluate the accuracy and limitations of contemporary staging modalities and investigate clinical outcomes in patients with MIBC who were managed with bladder preservation after NAT. Lastly, we discuss the predictive role of cisplatin-sensitizing DNA damage response (DDR) gene alterations as a foundational component to current prospective clinical trials evaluating bladder preservation in the setting of MIBC.

KW - Bladder cancer

KW - DNA damage response

KW - Genetic alteration

KW - Neoadjuvant therapy

KW - Predictors

UR - http://www.scopus.com/inward/record.url?scp=85146849667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146849667&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2023.01.001

DO - 10.1016/j.urolonc.2023.01.001

M3 - Review article

C2 - 36702704

AN - SCOPUS:85146849667

SN - 1078-1439

VL - 41

SP - 307

EP - 312

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

IS - 7

ER -

Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this